LJAC
ALNY icon

L.J. Altfest & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

L.J. Altfest & Co’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$436K Sell
1,317
-61
-4% -$20.8K 0.05% 236
2025
Q4 		$548K Buy
+1,378
New +$610K 0.06% 209
2025
Q2 		– Sell
-1,050
Closed -$284K – 335
2025
Q1 		$284K Buy
+1,050
New +$270K 0.04% 279
2024
Q3 		– Sell
-2,112
Closed -$513K – 334
2024
Q2 		$513K Buy
2,112
+12
+0.6% +$1.89K 0.07% 192
2024
Q1 		$314K Buy
2,100
+27
+1% +$4.5K 0.04% 254
2023
Q4 		$397K Buy
2,073
+475
+30% +$80.9K 0.06% 214
2023
Q3 		$283K Buy
1,598
+489
+44% +$93.3K 0.04% 247
2023
Q2 		$211K Sell
1,109
-18
-2% -$3.57K 0.03% 278
2023
Q1 		$226K Sell
1,127
-11
-1% -$2.31K 0.04% 253
2022
Q4 		$270K Sell
1,138
-38
-3% -$8.11K 0.04% 221
2022
Q3 		$235K Sell
1,176
-411
-26% -$78.4K 0.04% 239
2022
Q2 		$231K Sell
1,587
-18
-1% -$2.55K 0.04% 227
2022
Q1 		$262K Buy
+1,605
New +$245K 0.05% 220

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

L.J. Altfest & Co's ALNY Position: Q1 2026 in Review

L.J. Altfest & Co reduced its Alnylam Pharmaceuticals (ALNY) stake by 4.4% in Q1 2026, selling an estimated $20.8K and leaving 1,317 shares worth $436K. The position accounts for 0.05% of the portfolio, ranked #236.

L.J. Altfest & Co first reported a position in ALNY in Q1 2022 and has held it in 13 quarters since. The position peaked at $548K in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • L.J. Altfest & Co held 1,317 shares of Alnylam Pharmaceuticals worth $436K as of Q1 2026.
  • L.J. Altfest & Co sold 61 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $20.8K.
  • Alnylam Pharmaceuticals made up 0.05% of L.J. Altfest & Co's portfolio in Q1 2026, its #236 holding.
  • L.J. Altfest & Co first reported a position in Alnylam Pharmaceuticals in Q1 2022 and has held it in 13 quarters since.
  • L.J. Altfest & Co's Alnylam Pharmaceuticals position peaked at $548K in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on L.J. Altfest & Co's 13F filing for Q1 2026, filed 28 Apr 2026.